CTF8 Antibody

What is CTF8/CHTF8 and what is its biological significance?

CTF8 (also known as CHTF8) is a protein involved in chromosome transmission fidelity during cell division. Current research indicates it functions as a potential tumor suppressor, with overexpression studies demonstrating inhibition of prostate tumor cell growth . The protein has a molecular weight of approximately 51 kDa and is encoded by a gene that produces a protein product identified in UniProt as P0CG12 . Understanding CTF8's biological role is essential for researchers investigating chromosome stability, cell cycle regulation, and oncological mechanisms where disruptions in these processes may contribute to malignant transformation.

What types of CTF8 antibodies are available for research applications?

Research-grade CTF8 antibodies are available in several formats, with polyclonal antibodies being most common. These antibodies are typically generated in rabbits immunized with synthetic peptides corresponding to specific amino acid sequences of human CTF8. For example, commercially available CTF8 antibodies may target amino acid regions 2-33 of the human CTF8 protein . The antibodies are generally purified through protein A column chromatography followed by peptide affinity purification to ensure specificity . Both unconjugated antibodies and those with various conjugates may be available, though the primary research applications currently focus on unconjugated formats for Western blotting applications.

How should CTF8 antibodies be stored and handled to maintain optimal activity?

CTF8 antibodies require proper storage and handling to maintain their functional integrity. Based on standard antibody protocols and manufacturer recommendations, CTF8 antibodies are typically supplied in liquid format in PBS buffer containing 0.09% (w/v) sodium azide as a preservative . The recommended storage conditions are:

• Short-term storage (up to several weeks): 4°C

• Long-term storage: -20°C

Under these conditions, the antibodies typically maintain activity for approximately 6 months from the date of receipt . When handling these antibodies, researchers should:

• Avoid repeated freeze-thaw cycles

• Aliquot antibodies before freezing for long-term storage

• Exercise appropriate caution when handling due to the presence of sodium azide, which is toxic and hazardous

• Allow antibodies to reach room temperature before opening vials to prevent condensation

What is the recommended protocol for using CTF8 antibody in Western blotting?

For Western blotting applications with CTF8 antibodies, researchers should follow this methodological approach:

• Sample preparation: Prepare protein lysates from cells or tissues of interest using standard lysis buffers containing protease inhibitors.

• Protein separation: Separate proteins by SDS-PAGE using a gel percentage appropriate for detecting a ~51 kDa protein (typically 10%).

• Transfer: Transfer proteins to a PVDF or nitrocellulose membrane.

• Blocking: Block the membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute the CTF8 antibody at a 1:2000 ratio in blocking solution and incubate overnight at 4°C .

• Washing: Wash the membrane 3-5 times with TBST.

• Secondary antibody: Incubate with an appropriate HRP-conjugated secondary antibody (anti-rabbit IgG for rabbit-derived primary antibodies).

• Detection: Visualize using chemiluminescence reagents and document results.

This protocol should allow for specific detection of CTF8 protein in human samples, with expected molecular weight around 51 kDa.

How can CTF8 antibody validation be performed to ensure specificity for tumor biology research?

Validating CTF8 antibodies for tumor biology research requires a multi-faceted approach to confirm specificity and reliability, particularly important given CTF8's potential role as a tumor suppressor. A comprehensive validation protocol includes:

• Positive and negative cell line controls: Test the antibody on cell lines known to express CTF8 at different levels, including prostate cancer cell lines where CTF8 has demonstrated tumor suppressor activity . Include cell lines with CRISPR/Cas9 knockout of CTF8 as negative controls.

• siRNA knockdown validation: Perform knockdown experiments using CTF8-specific siRNA in positive control cell lines, followed by Western blotting to confirm decreased signal intensity correlating with decreased protein expression.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide (amino acids 2-33 of human CTF8) before application in Western blotting to confirm signal specificity.

• Orthogonal method validation: Compare protein expression detected by the antibody with mRNA expression levels determined by qRT-PCR.

• Cross-reactivity assessment: Test the antibody on protein lysates from multiple species to determine species specificity and potential cross-reactivity.

• Reproducibility assessment: Perform replicate experiments using different batches of the antibody to confirm consistent staining patterns.

Document validation results thoroughly with quantitative measurements and representative images to establish a reliable foundation for subsequent research applications.

What are the methodological considerations for using CTF8 antibodies in multi-parameter flow cytometry?

While the currently available CTF8 antibody is primarily validated for Western blotting , researchers interested in adapting it for flow cytometry should consider the following methodological approaches:

• Antibody conjugation: Since commercial CTF8 antibodies are often unconjugated , researchers may need to perform custom conjugation with fluorophores suitable for their cytometry panels. Consider using NHS-ester chemistry conjugation kits with fluorophores like PE, APC, or Alexa Fluor dyes.

• Fixation and permeabilization optimization:

  • Test multiple fixation protocols (e.g., 1-4% paraformaldehyde, methanol, or commercial fixatives)

  • Compare permeabilization reagents (e.g., saponin, Triton X-100, commercial buffers) at various concentrations

  • Develop a fixation/permeabilization matrix to identify optimal conditions

• Titration assay: Perform a detailed antibody titration series (typically 0.1-10 μg/mL) to determine the optimal concentration that provides maximum signal-to-noise ratio.

• Controls to include:

  • Fluorescence minus one (FMO) controls

  • Isotype controls matched to the CTF8 antibody (rabbit polyclonal Ig fraction)

  • Positive control cells with confirmed CTF8 expression

  • Negative control cells with CTF8 knockdown

• Co-staining considerations: When designing multi-parameter panels, consider potential spectral overlap and compensation requirements, particularly if studying CTF8 in complex cell populations.

How can CTF8 antibodies be used to investigate the relationship between CTF8 expression and cancer progression?

Investigating the relationship between CTF8 expression and cancer progression requires methodical experimental approaches using validated CTF8 antibodies. Given CTF8's potential tumor suppressor role in prostate cancer , a comprehensive research strategy might include:

• Tissue microarray (TMA) analysis:

  • Construct TMAs containing samples from normal prostate tissue, benign prostatic hyperplasia, and prostate cancers of various Gleason grades

  • Perform immunohistochemistry using validated CTF8 antibody

  • Score expression patterns (nuclear vs. cytoplasmic) and intensity

  • Correlate expression patterns with clinicopathological parameters and patient outcomes

• Cell line panel characterization:

  • Profile CTF8 expression across prostate cancer cell line panels representing different disease stages using Western blotting

  • Correlate expression levels with established cell line characteristics (androgen sensitivity, metastatic potential, etc.)

• Functional studies:

  • Develop stable cell lines with CTF8 overexpression or knockdown

  • Assess changes in:

    • Proliferation rates (MTT/XTT assays)

    • Colony formation capacity

    • Migration/invasion potential (transwell assays)

    • Anchorage-independent growth (soft agar assays)

• Molecular pathway analysis:

  • Use co-immunoprecipitation with CTF8 antibodies to identify protein interaction partners

  • Perform Western blotting to assess how CTF8 expression affects key signaling pathways

  • Utilize phospho-specific antibodies to evaluate pathway activation states

• In vivo models:

  • Develop xenograft models using cells with modified CTF8 expression

  • Monitor tumor growth, metastasis, and response to standard therapies

  • Analyze tumors by immunohistochemistry to confirm sustained CTF8 expression changes

What are the considerations for using CTF8 antibodies in chromatin immunoprecipitation (ChIP) experiments?

While the currently available CTF8 antibody is primarily validated for Western blotting , researchers interested in ChIP applications should consider these methodological approaches:

• Antibody suitability assessment:

  • Verify the antibody recognizes native (non-denatured) CTF8 protein through immunoprecipitation

  • Test multiple antibody concentrations (1-10 μg per ChIP reaction)

  • Consider antibodies targeting different epitopes of CTF8 beyond the amino acids 2-33 region

• Crosslinking optimization:

  • Test formaldehyde concentrations (0.5-2%) and crosslinking times (5-20 minutes)

  • For protein-protein interactions, consider dual crosslinking with DSG (disuccinimidyl glutarate) followed by formaldehyde

• Sonication parameters:

  • Optimize sonication conditions to yield chromatin fragments between 200-500 bp

  • Verify fragmentation by agarose gel electrophoresis before proceeding

• Positive controls:

  • Include ChIP for known chromatin-associated factors (e.g., histones)

  • Use cell lines with confirmed CTF8 expression

• Negative controls:

  • IgG fraction from non-immunized rabbits

  • ChIP in cell lines with CTF8 knockdown

• Data validation:

  • Perform biological replicates (minimum n=3)

  • Validate enriched regions by qPCR before proceeding to sequencing

  • Compare ChIP-seq peaks with published datasets for chromosomal regions involved in mitotic processes

How can CTF8 antibodies be combined with other molecular tools to elucidate CTF8's role in chromosome transmission fidelity?

Integrating CTF8 antibodies with complementary molecular approaches can provide deeper insights into CTF8's functional role in chromosome transmission. A multi-modal research strategy might include:

• Proximity ligation assays (PLA):

  • Use CTF8 antibody in combination with antibodies against suspected interaction partners

  • Visualize and quantify protein-protein interactions at the single-molecule level

  • Map interactions throughout the cell cycle using synchronized cell populations

• Live-cell imaging with engineered antibody fragments:

  • Develop Fab fragments from CTF8 antibodies

  • Conjugate with cell-permeable fluorophores

  • Perform time-lapse microscopy to track CTF8 localization during mitosis

• CRISPR/Cas9 genome editing combined with rescue experiments:

  • Generate CTF8 knockout cell lines

  • Reintroduce wild-type or mutant CTF8 variants

  • Use CTF8 antibodies to confirm expression and localization patterns

  • Assess chromosome segregation errors through immunofluorescence

• Proteomic analysis:

  • Perform immunoprecipitation with CTF8 antibodies followed by mass spectrometry

  • Identify novel interaction partners

  • Validate interactions through reciprocal co-immunoprecipitation

• Chromosome transmission fidelity assays:

  • Measure chromosome segregation accuracy in cells with modified CTF8 expression

  • Quantify aneuploidy rates using fluorescence in situ hybridization (FISH)

  • Correlate CTF8 expression levels (determined by Western blotting) with segregation error frequencies

What are common causes of non-specific binding with CTF8 antibodies and how can they be addressed?

Non-specific binding is a common challenge when working with antibodies including CTF8 antibodies. Researchers can systematically address these issues through the following approaches:

• Blocking optimization:

  • Test different blocking agents (BSA, non-fat dry milk, normal serum, commercial blockers)

  • Increase blocking time (from 1 to 3 hours)

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

• Antibody dilution optimization:

  • While 1:2000 is recommended for Western blotting , create a dilution series (1:1000 to 1:5000)

  • Prepare antibody dilutions in fresh blocking buffer immediately before use

  • Consider overnight incubation at 4°C rather than shorter incubations at room temperature

• Buffer modifications:

  • Add 5% glycerol to reduce non-specific binding

  • Include 0.1-0.5 M NaCl to disrupt low-affinity interactions

  • Consider adding 0.1% SDS for Western blotting applications to enhance specificity

• Sample preparation considerations:

  • Ensure complete protein denaturation for Western blotting

  • Remove particulates from lysates through high-speed centrifugation

  • Quantify protein to ensure consistent loading

• Secondary antibody controls:

  • Include secondary-only controls to identify background from secondary antibody

  • Use highly cross-adsorbed secondary antibodies

  • Consider using secondary antibodies from different manufacturers

How can researchers optimize fixation and epitope retrieval when using CTF8 antibodies for immunohistochemistry?

While the primary validated application for current CTF8 antibodies is Western blotting , researchers adapting these antibodies for immunohistochemistry should consider these methodological optimizations:

• Fixation optimization matrix:

  Fixative	Concentration	Duration	Potential Benefits
  Neutral buffered formalin	10%	24-48 hours	Standard fixation, good morphology
  Paraformaldehyde	2-4%	12-24 hours	Reduced epitope masking
  Methanol/Acetone	100%	10-20 minutes	Good for nuclear proteins
  Zinc-based fixatives	Commercial preparation	12-24 hours	Improved epitope preservation

• Epitope retrieval optimization:

  • Heat-induced epitope retrieval (HIER):

    • Test multiple buffer systems (citrate pH 6.0, EDTA pH 8.0, Tris-EDTA pH 9.0)

    • Compare different heating methods (microwave, pressure cooker, water bath)

    • Optimize heating times (10-30 minutes)

  • Enzymatic retrieval:

    • Test proteinase K, trypsin, or pepsin at various concentrations

    • Optimize digestion times (5-20 minutes)

    • Combine with gentle HIER for synergistic effects

• Antibody incubation parameters:

  • Test both room temperature (1-2 hours) and 4°C (overnight) incubations

  • Evaluate different antibody diluents (commercial preparations vs. lab-made)

  • Consider using amplification systems (polymer detection, tyramide signal amplification)

• Background reduction strategies:

  • Include avidin/biotin blocking for biotin-based detection systems

  • Use hydrogen peroxide block before primary antibody incubation

  • Consider protein block with 5-10% normal serum from the species of the secondary antibody

• Validation approaches:

  • Compare staining patterns with RNA in situ hybridization

  • Include known positive control tissues

  • Run peptide competition controls with the immunizing peptide (amino acids 2-33)

What are the key technical challenges in using CTF8 antibodies for studying protein-protein interactions?

Investigating protein-protein interactions using CTF8 antibodies presents several technical challenges that researchers should address methodically:

• Preservation of native protein complexes:

  • Use gentle lysis buffers (avoid strong detergents like SDS)

  • Maintain physiological pH (7.2-7.4) during extraction

  • Include protease and phosphatase inhibitors to prevent complex degradation

  • Consider stabilizing interactions with chemical crosslinkers (DSP, formaldehyde)

• Antibody binding characteristics:

  • Verify the antibody's epitope (amino acids 2-33) doesn't overlap with interaction domains

  • Test antibody binding under non-denaturing conditions

  • Consider using multiple antibodies targeting different CTF8 epitopes

• Co-immunoprecipitation optimization:

  • Test various elution conditions (pH, ionic strength, competitive elution)

• Validation strategies:

  • Perform reciprocal co-IPs when possible

  • Use size exclusion chromatography to confirm complex formation

  • Employ proximity-based techniques (BioID, APEX) as orthogonal methods

• Controls to include:

  • IgG fraction control from non-immunized rabbits

  • Pre-immune serum controls

  • Input controls (5-10% of starting material)

  • Negative control lysates (CTF8 knockdown cells)

How might CTF8 antibodies be utilized in single-cell analysis technologies?

As single-cell technologies revolutionize biological research, CTF8 antibodies could be adapted for these emerging applications through innovative approaches:

• Mass cytometry (CyTOF) applications:

  • Conjugate CTF8 antibodies with rare earth metals for multi-parameter single-cell analysis

  • Combine with cell cycle markers to assess CTF8 dynamics during mitosis

  • Develop panels to simultaneously examine chromosome segregation markers and CTF8

• Single-cell Western blotting:

  • Adapt validated Western blotting protocols for microfluidic single-cell Western platforms

  • Calibrate antibody concentrations for reduced volumes

  • Correlate CTF8 expression with cellular phenotypes at single-cell resolution

• Imaging mass cytometry:

  • Use metal-tagged CTF8 antibodies to visualize spatial distribution in tissue sections

  • Multiplex with tumor markers and chromosome segregation proteins

  • Analyze tumor heterogeneity with respect to CTF8 expression patterns

• CITE-seq integration:

  • Develop oligonucleotide-tagged CTF8 antibodies for cellular indexing of transcriptomes and epitopes

  • Correlate CTF8 protein levels with transcriptional profiles at single-cell resolution

  • Identify gene expression signatures associated with varying CTF8 levels

• Technical optimization requirements:

  • Antibody conjugation efficiency verification

  • Single-cell validation with fluorescence microscopy

  • Spike-in controls for quantitative analysis

  • Batch effect correction strategies

What are the potential applications of CTF8 antibodies in studying the relationship between chromosome instability and cancer therapy resistance?

Given CTF8's role in chromosome transmission fidelity and its potential tumor suppressor function , CTF8 antibodies could be valuable tools for investigating therapy resistance mechanisms:

• Therapy response monitoring:

  • Profile CTF8 expression before and after chemotherapy treatment

  • Correlate expression changes with development of resistance

  • Analyze chromosome segregation errors in resistant vs. sensitive cells

• Patient-derived xenograft (PDX) models:

  • Characterize CTF8 expression in PDX models of responsive vs. resistant tumors

  • Perform serial sampling during treatment to monitor dynamic changes

  • Correlate with genomic instability markers

• Combination therapy rational design:

  • Screen for compounds that modulate CTF8 expression or function

  • Test combinations with standard chemotherapeutics

  • Use CTF8 antibodies to monitor mechanistic effects on protein level and localization

• Predictive biomarker development:

  • Develop immunohistochemistry protocols using CTF8 antibodies

  • Create scoring systems based on expression levels and subcellular localization

  • Correlate with clinical outcomes in retrospective patient cohorts

• Research hypothesis: Loss of CTF8 function may promote genomic instability, leading to accelerated acquisition of therapy resistance mutations. CTF8 antibody-based detection methods could identify patients at higher risk for resistance development.

How can researchers integrate computational approaches with CTF8 antibody data to gain systems-level insights?

Modern research increasingly combines experimental antibody-based data with computational approaches for deeper biological insights. For CTF8 research, these integrative approaches might include:

• Network analysis of protein interaction data:

  • Use CTF8 antibody-based immunoprecipitation followed by mass spectrometry

  • Apply protein-protein interaction network algorithms to identify key nodes

  • Perform pathway enrichment analysis to place CTF8 in functional contexts

  • Visualize interaction networks with tools like Cytoscape or STRING

• Multi-omics data integration:

  • Correlate CTF8 protein levels (determined by immunoblotting) with:

    • Transcriptomic data (RNA-seq)

    • Genomic alterations (WGS/WES)

    • Epigenomic profiles (ChIP-seq, ATAC-seq)

  • Apply dimension reduction techniques (PCA, t-SNE, UMAP) to visualize relationships

  • Utilize Bayesian network analysis to infer causal relationships

• Machine learning applications:

  • Train predictive models using quantitative CTF8 antibody staining data

  • Develop image analysis algorithms for automated evaluation of CTF8 immunohistochemistry

  • Create classifiers to predict therapy response based on CTF8 expression patterns

  • Employ feature selection algorithms to identify key determinants of CTF8 function

• Structural biology integration:

  • Use CTF8 antibody epitope data (amino acids 2-33) to refine protein structure predictions

  • Perform molecular dynamics simulations to understand conformational changes

  • Model protein-protein interactions based on co-immunoprecipitation data

• Large-scale database mining:

  • Query cancer genomics databases (TCGA, ICGC) for CTF8 alterations

  • Correlate with patient outcomes and clinicopathological features

  • Generate testable hypotheses for validation with CTF8 antibodies

By integrating computational approaches with experimental CTF8 antibody data, researchers can gain systems-level insights that would not be possible with either approach alone.